Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations
about
Synthetic promoter library for modulation of actinorhodin production in Streptomyces coelicolor A3(2).Genome shuffling and ribosome engineering of Streptomyces actuosus for high-yield nosiheptide production.Generation and study of the strains of streptomycetes - heterologous hosts for production of moenomycin.Activation of Antibiotic Production in Bacillus spp. by Cumulative Drug Resistance Mutations.Antimicrobial drug resistance affects broad changes in metabolomic phenotype in addition to secondary metabolismActivation and products of the cryptic secondary metabolite biosynthetic gene clusters by rifampin resistance (rpoB) mutations in actinomycetes.Disruption of rimP-SC, encoding a ribosome assembly cofactor, markedly enhances the production of several antibiotics in Streptomyces coelicolor.Activation of dormant bacterial genes by Nonomuraea sp. strain ATCC 39727 mutant-type RNA polymerase.A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.Improvement of daptomycin production in Streptomyces roseosporus through the acquisition of pleuromutilin resistance.Identification and characterization of a novel multidrug resistance operon, mdtRP (yusOP), of Bacillus subtilis.Antibiotic overproduction by rpsL and rsmG mutants of various actinomycetesIdentification of two novel anti-fibrotic benzopyran compounds produced by engineered strains derived from Streptomyces xiamenensis M1-94P that originated from deep-sea sediments.Identification of a Novel Lincomycin Resistance Mutation Associated with Activation of Antibiotic Production in Streptomyces coelicolor A3(2).Rifampicin-Resistance Mutations in the rpoB Gene in Bacillus velezensis CC09 have Pleiotropic Effects.The mthA mutation conferring low-level resistance to streptomycin enhances antibiotic production in Bacillus subtilis by increasing the S-adenosylmethionine pool sizeStrain improvement in actinomycetes in the postgenomic era.Molecular insights on the biosynthesis of antitumour compounds by actinomycetes.Activation of dormant secondary metabolism neotrehalosadiamine synthesis by an RNA polymerase mutation in Bacillus subtilis.The regulation of the secondary metabolism of Streptomyces: new links and experimental advances.New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters.Towards a new science of secondary metabolism.Activating the expression of bacterial cryptic genes by rpoB mutations in RNA polymerase or by rare earth elements.Spontaneous and induced mutations to rifampicin, streptomycin and spectinomycin resistances in actinomycetes: mutagenic mechanisms and applications for strain improvement.Genetic manipulation of secondary metabolite biosynthesis for improved production in Streptomyces and other actinomycetes.Prospecting for new bacterial metabolites: a glossary of approaches for inducing, activating and upregulating the biosynthesis of bacterial cryptic or silent natural products.Engineering microbial hosts for production of bacterial natural productsAn overview of rapamycin: from discovery to future perspectives.Comparative mass spectrometry-based metabolomics strategies for the investigation of microbial secondary metabolites.Insights into microbial cryptic gene activation and strain improvement: principle, application and technical aspects.Lincomycin at Subinhibitory Concentrations Potentiates Secondary Metabolite Production by Streptomyces spp.Strategies for the discovery of new natural products by genome mining.A novel two-component system involved in secretion stress response in Streptomyces lividans.Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters.An insight into the "-omics" based engineering of streptomycetes for secondary metabolite overproduction.Transcriptional regulation and increased production of asukamycin in engineered Streptomyces nodosus subsp. asukaensis strains.Ribosome engineering and fermentation optimization leads to overproduction of tiancimycin A, a new enediyne natural product from Streptomyces sp. CB03234.Enhanced ε-poly-L-lysine production by inducing double antibiotic-resistant mutations in Streptomyces albulus.Rational engineering of Streptomyces albus J1074 for the overexpression of secondary metabolite gene clusters.Characterization of representative rpoB gene mutations leading to a significant change in toyocamycin production of Streptomyces diastatochromogenes 1628.
P2860
Q30435989-DBBA249D-270E-49BD-B627-811A3194759CQ34420023-49AB500A-BAC7-46B2-8B0D-CCF706144565Q35004076-E88D6FCD-B254-4B0A-9B82-128372B82377Q36290652-4F3B70AD-A4B7-495F-9ED1-DDD6F97C7CCEQ36598165-2DD66CA6-DBB9-48EC-BB51-0651946B14B5Q36970549-90E7D826-4A67-4F2A-A715-CB7E06F8230DQ37028451-0446739D-BCA9-4178-BB6E-0D4F36229211Q37075541-DC531733-C872-4FF7-B9BA-76E27C16605FQ37115665-39AA4E35-BEF2-4C76-8FE4-F111EC11AD14Q37196863-1B5A7ECB-EE3F-4C59-8BB2-E0B164E86B5DQ37204093-2AB86EC6-1F4D-4856-8701-C8578EE9E059Q37256192-65568FA9-FA43-4B3C-91A4-CDC06D22FDD7Q37304042-AC9AEE3C-9C7A-4D12-A7EA-FD95BAA5A938Q37612966-815D9640-23C0-4A36-BF88-843196C9FDEBQ37637518-0636FD39-DEF0-4B78-A14A-8BA6B475686AQ37713211-A7B5549E-A889-438A-B072-BA6F3E4451F6Q37831207-87069CC4-160E-4054-B822-0E30C525EEA6Q37845949-7A57295F-614B-4C02-81BE-6FE0E3DB8227Q37867911-5E80C2A2-4B20-4A59-BB22-08EED7E37230Q37879562-A399DBB4-2CBF-4B6A-B10D-E8742A94A2F0Q38059156-557C4CF4-68C6-431D-BE10-7A3800B37C91Q38101244-A972875C-3C04-452F-B649-BE2428CA2513Q38152725-A57BE77F-9CAB-4F71-A9BF-A8496AA19B78Q38239461-C7E24877-68F3-4EE4-944A-CA49FCB5ADFFQ38585753-21E6CAED-B7AB-4BA0-B02D-62637681852FQ38625630-185DA93C-3CEC-467B-ACB0-41338FF2DB94Q38806940-B7112880-EA5E-4E75-96DE-1D9A70559878Q38822715-6C9765FD-2F56-43E2-A80D-66FABCB2448BQ38823592-4E861ECD-4977-4D02-857C-29FC3A2C30ECQ38887214-84386A86-473A-440E-914C-0765DD1A8B18Q40314872-441373BD-17E2-4F58-B864-31D9580966EDQ40398989-E5C42496-9DA6-4C87-8268-7961DFF95D9DQ41147041-B061A11E-296E-42B1-93FA-B36B6C7E1B48Q41761257-120A867D-3A39-4D05-967B-35174E4BDF2BQ42181821-80041FE4-9858-47B7-9D32-38480E2A339FQ43168297-85AC13AF-1B1B-431D-9787-3865EAB769F8Q48111896-66615304-18CC-434C-942B-83BB4537C5A7Q48945482-8979A64C-95AC-40D8-BF31-9792606A0858Q49900720-7542142D-360F-433E-BD14-5A95D2061198Q50889575-4B4A0DCC-CFE0-4153-887D-BCD75AF9582E
P2860
Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dramatic activation of antibio ...... tive drug resistance mutations
@ast
Dramatic activation of antibio ...... tive drug resistance mutations
@en
Dramatic activation of antibio ...... tive drug resistance mutations
@nl
type
label
Dramatic activation of antibio ...... tive drug resistance mutations
@ast
Dramatic activation of antibio ...... tive drug resistance mutations
@en
Dramatic activation of antibio ...... tive drug resistance mutations
@nl
prefLabel
Dramatic activation of antibio ...... tive drug resistance mutations
@ast
Dramatic activation of antibio ...... tive drug resistance mutations
@en
Dramatic activation of antibio ...... tive drug resistance mutations
@nl
P2860
P356
P1476
Dramatic activation of antibio ...... tive drug resistance mutations
@en
P2093
Takeshi Hosaka
P2860
P304
P356
10.1128/AEM.02800-07
P407
P50
P577
2008-05-01T00:00:00Z